The UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in a dedicated headquarters for early-stage research.
Digital technologies are both helping to transform the public’s perception of dementia, and enabling everyone to help scientific research into the disease by playing a smartphone game that tests navigation skills.
Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered by people with dementia with Lewy bodies (DLB).
